#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements

Peter Attia introduces an episode of The Drive focused on sleep pharmacology, explaining the biological importance of sleep and how modern environments disrupt our natural sleep systems. He outlines the four key pillars of sleep issues: sleep pressure, circadian timing, hyperarousal, and sleep architecture.

Peter Attia discusses the behavioral foundation of sleep hygiene, emphasizing circadian and homeostatic alignment. He also highlights the importance of ruling out medical conditions like restless leg syndrome, obstructive sleep apnea, and mood disorders before starting sleep medications.

Peter Attia discusses the underlying mechanisms of insomnia, highlighting how hyperarousal and evolutionary mismatch drive modern sleep issues. He explains why Cognitive Behavioral Therapy for Insomnia (CBT-I) is the preferred first-line treatment and warns against the misuse of sleep medications like benzodiazepines, which can mask sleep issues by causing memory impairment rather than improving sleep quality.

Peter Attia explains the difference between true physiological sleep and drug-induced sedation, highlighting how sleep medications alter natural sleep architecture. He details the mechanism of action, benefits, and severe risks associated with benzodiazepines like Xanax and Valium, before introducing second-generation Z-drugs like Ambien.

Peter Attia compares traditional Z-drugs like Ambien with newer dual orexin receptor antagonists (DORAs) like Dayvigo. While Z-drugs carry significant risks of dependency, memory impairment, and complex sleep behaviors, DORAs offer a safer alternative by turning down the brain's wakefulness system without disrupting natural sleep architecture.

Peter Attia discusses how sleep, particularly deep non-REM sleep, facilitates glymphatic clearance of toxic proteins like beta amyloid and tau. He reviews promising research on Dual Orexin Receptor Antagonists (DORAs) like Belsomra and Davego, which may help reduce these Alzheimer's-related proteins, unlike traditional sleep aids like Ambien. While early human and animal data are intriguing, Attia emphasizes that larger clinical trials are required before recommending these drugs for neurodegenerative prevention.

Peter Attia explains the pharmacokinetics and side effects of Dual Orexin Receptor Antagonists (DORAs) like Belsomra, Dayvigo, and Quviviq. He then transitions to discussing melatonin, clarifying its role as a circadian signal rather than a direct sedative, and highlights the quality control issues with commercial supplements.

Peter Attia discusses various pharmacological options for sleep, starting with melatonin receptor agonists like Ramelteon, which are useful for circadian realignment. He highlights trazodone as an excellent off-label sleep aid that preserves deep sleep, while cautioning against the long-term use of over-the-counter antihistamines like Benadryl and NyQuil due to their anticholinergic risks.

Peter Attia evaluates the scientific evidence behind popular sleep supplements, including glycine, magnesium, ashwagandha, and phosphatidylserine. He highlights the discrepancy between marketing claims and clinical data, while emphasizing the critical importance of quality control and third-party testing like USP.

Peter Attia concludes the discussion on sleep pharmacology by emphasizing the importance of targeting the correct biological systems rather than guessing. He advises using independent testing organizations like ConsumerLab and Labdoor to verify supplement quality before purchasing.